ADR 10.0% 1.8¢ adherium limited

AstraZen study outcome, page-6

  1. 352 Posts.
    lightbulb Created with Sketch. 38
    Baffling indeed in such a short time for such a hot sector.

    However on the assumption we can take management at its word, there is no immediate need to raise capital and dilution of investors is not presently being considered. That's a big statement. And after all this work with AZ, I couldn't imagine them wanting anything other than ADR to succeed.

    So Cash is OK for now and I think it'd be safe to assume we have a supportive customer in AZ who have a vested interest in a healthy ADR.

    And finally today we have one of the largest shareholders (albeit indirect) and experienced directors at the helm in Jeremy.

    BUT for cash, one could argue that ADR is advanced from a technology perspective today as its ever been.

    If Jeremy can manage the company's finances this could be the opportunity of a lifetime. At $5m the market is a non believer. But IF Jeremy can execute, and with his pedigree I believe the PROBABILITY is pretty good, we could be well rewarded. Failing that, I won't be paying CGT for a long time.






 
watchlist Created with Sketch. Add ADR (ASX) to my watchlist
(20min delay)
Last
1.8¢
Change
-0.002(10.0%)
Mkt cap ! $13.65M
Open High Low Value Volume
1.8¢ 1.8¢ 1.8¢ $875 48.60K

Buyers (Bids)

No. Vol. Price($)
1 21110 1.8¢
 

Sellers (Offers)

Price($) Vol. No.
2.0¢ 494887 1
View Market Depth
Last trade - 16.10pm 12/07/2024 (20 minute delay) ?
ADR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.